A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese… (NCT07060885) | Clinical Trial Compass
Active — Not RecruitingPhase 3
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
China327 participantsStarted 2025-09-01
Plain-language summary
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
Who can participate
Age range
12 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female Chinese subjects aged 12-65 years
* A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening
* Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period
* Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period
* Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening
* Lung function ≥ 70% of predicted value
Exclusion Criteria:
* Sensitised and regularly exposed to perennial allergens
* Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation
* Asthma requiring treatment with high dose of inhaled corticosteroid
* A relevant history of systemic allergic reaction
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is measuring something called the 'total combined rhinitis score' — can you explain what that score captures day-to-day, and how meaningful an improvement in that score would actually feel for someone managing my symptoms?
2Since this is a Phase 3 trial and it's no longer actively recruiting, does that mean I've missed the window to participate, and if so, are there similar completed or ongoing studies I could look into instead?
3The trial uses a sublingual tablet — a dissolvable tablet placed under the tongue — for house dust mite allergy; how does this approach compare to allergy shots or other standard treatments I could start right now?
4This study is focused on Chinese participants aged 12 to 65 with allergic rhinitis or rhinoconjunctivitis — given my specific situation, do you think my symptoms are a good match for what this trial was designed to treat?
5Because the trial is in Phase 3, there's more safety data available than in earlier phases, but it's still a research study — are there any known or suspected side effects from house dust mite sublingual tablets that we should talk through before I consider any next steps?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Average daily total combined rhinitis score (TCRS) during the primary efficacy assessment period.
Timeframe: 4 weeks (primary efficacy assessment period), starting 24 weeks after initiation of IMP.